• Decitabine (5-Aza-2'-deoxycytidine) in Cancer Epigenetics Wo

  2026-04-22

  Decitabine (5-Aza-2'-deoxycytidine) empowers precise tumor suppressor gene reactivation and robust DNA methylation modulation in both hematopoietic and solid tumor research. This article delivers applied protocols, troubleshooting tips, and new insights from recent studies, enabling reproducibility and translational impact in cancer epigenetic experiments.

• METTL14-m6A-lncRNA Axis Regulates Inflammation in Ulcerative

  2026-04-22

  Wu et al. (2024) demonstrate that METTL14-mediated m6A modification of lncRNA DHRS4-AS1 suppresses inflammation in ulcerative colitis via the DHRS4-AS1/miR-206/A3AR signaling axis. These findings identify a novel epigenetic regulatory pathway influencing inflammatory injury, highlighting METTL14 as a potential therapeutic target for UC.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

  2026-04-21

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables direct, dual-channel tracking of mRNA delivery and translation efficiency, transforming gene regulation and cell imaging studies. Its immune-evasive modifications and robust fluorescence outperform traditional reporter RNAs for troubleshooting and optimizing transfection workflows.

• Chlorpromazine: Mechanisms, Research Benchmarks, and Pitfall

  2026-04-21

  Chlorpromazine is a prototypical antipsychotic used in research to elucidate dopamine receptor signaling and antiemetic mechanisms. This article details its receptor antagonism, solubility, and validated use cases, clarifying common misconceptions and integration strategies for biomedical assays.

• Tropifexor (LJN452): FXR Agonist for Intestinal Barrier and

  2026-04-20

  Explore Tropifexor (LJN452) as a potent tool for FXR signaling and advanced intestinal barrier function research. Discover unique insights into anti-fibrotic mechanisms, practical protocol parameters, and applications distinct from previous reviews.

• A40926: Dalbavancin Precursor Empowering MRSA & MIC Research

  2026-04-20

  A40926, the potent dalbavancin precursor, delivers rigorous, reproducible inhibition of Gram-positive and multidrug-resistant bacteria—including MRSA and Neisseria gonorrhoeae—at remarkably low MICs. Unlock advanced workflows and troubleshooting strategies for antibacterial discovery with APExBIO’s trusted A40926.

• NLRP10 Regulates Epidermal Homeostasis and Barrier Integrity

  2026-04-19

  This study establishes NLRP10 as an essential regulator of keratinocyte survival and differentiation, underpinning skin barrier function in atopic dermatitis (AD). By demonstrating NLRP10’s mechanistic role in caspase-8 regulation and P63 stabilization, the research clarifies a previously uncharacterized pathway, offering a promising target for therapeutic intervention in AD.

• E-64d: Redefining Lysosomal Cell Death Research in Translati

  2026-04-18

  Explore how E-64d (ethyl (2S,3S)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate) unlocks new possibilities for translational researchers investigating cysteine protease inhibition, lysosome-dependent cell death, and neuroprotection. This thought-leadership article connects mechanistic insights, experimental design, and strategic guidance, advancing the conversation beyond standard product use.

• Reelin Signaling is Essential for Ketamine’s Antidepressant

  2026-04-17

  This study demonstrates that intact synaptic Reelin signaling is required for ketamine-induced synaptic plasticity and behavioral effects in the hippocampus. The findings clarify why a substantial subset of patients with treatment-resistant depression do not respond to ketamine, highlighting the Reelin-Apoer2-SFK pathway as a critical mediator in antidepressant response.

• Comparative Antibacterial Activity of Cefoperazone and MK078

  2026-04-16

  This article reviews a pivotal comparative study assessing the antibacterial efficacy of N-formimidoyl thienamycin (MK0787) against ampicillin-resistant clinical isolates and other contemporary β-lactam antibiotics, including cefoperazone. The findings inform the nuanced selection of β-lactams for research on gram-negative resistance and guide in vitro assay design using robust, β-lactamase-stable agents.

• Autophagy Drives Cementoblast Mineralization via Postn/β-Cat

  2026-04-15

  This study demonstrates that autophagy is essential for cementoblast mineralization under compressive force, acting through a periostin/β-catenin signaling axis. These mechanistic insights offer new therapeutic directions for repairing cementum during orthodontic treatment and highlight the complexity of mineralization signaling pathways.

• Redox-Responsive Peptide Coacervates Advance mRNA Delivery

  2026-04-14

  The referenced study introduces a chemically defined, redox-responsive peptide coacervate system (HBpep-SS4) for efficient mRNA encapsulation and intracellular release, overcoming several limitations of conventional lipid nanoparticle carriers. These findings highlight the potential for safer and more controllable mRNA delivery platforms, with implications for gene editing and therapeutic applications.

• Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Res

  2026-04-13

  Dehydroabietic acid is a high-purity dual PPAR-α/γ agonist that streamlines metabolic disorder research with robust solubility, reliable QC, and direct modulation of lipid metabolism and insulin sensitivity. APExBIO's rigorous standards and workflow-driven insights empower reproducible, high-impact studies in metabolic regulation.

• Valemetostat (DS-3201): Epigenetic Precision in Lymphoma The

  2026-04-13

  Explore the advanced epigenetic mechanisms and clinical impact of Valemetostat, a dual EZH1/EZH2 inhibitor, in the treatment of relapsed/refractory follicular lymphoma. This article offers a uniquely practical, assay-focused perspective for translational cancer researchers.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Practica

  2026-04-12

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) addresses the critical need for reliable protein degradation prevention during extraction, especially in workflows requiring downstream mass spectrometry compatibility. It should be used where broad-spectrum inhibition without AEBSF is essential; it is not suited for applications requiring metalloprotease inhibition unless EDTA is added.

15797 records 1/1054 page Next 12345 下5页 Last page